Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nitrofurazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.87 |
| ▸ | TP53 | P04637 | 3/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.87 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.87 |
| ▸ | HTT | P42858 | 6/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | MITF | O75030 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrofurazone SCHEMBL3681048 | 0.93 | LMNA (1.00) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL25416 | 0.93 | LMNA (1.00) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL25417 | 0.93 | LMNA (1.00) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL28198181 | 0.92 | LMNA (0.97) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL28871281 | 0.91 | LMNA (0.81) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL28285714 | 0.91 | LMNA (0.94) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL9928793 | 0.90 | LMNA (0.87) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL28246849 | 0.88 | LMNA (0.83) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL9054779 | 0.85 | LMNA (0.83) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 | |
| Nitrofurazone SCHEMBL8448657 | 0.83 | LMNA (0.76) | LMNAALDH1A1SMN1; SMN2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |